Actinium Pharmaceuticals, Inc. (FRA:7AY1)
Germany · Delayed Price · Currency is EUR | Market Cap | 42.68M +10.3% |
| Revenue (ttm) | 30.71M |
| Net Income | 9.90M |
| EPS | 0.32 |
| Shares Out | n/a |
| PE Ratio | 4.22 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,500 |
| Open | 1.342 |
| Previous Close | 1.194 |
| Day's Range | 1.342 - 1.342 |
| 52-Week Range | 0.634 - 1.426 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody... [Read more]
News
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑target...
Actinium Pharmaceuticals’ ATNM-400 shows anti-tumor activity in prostate cancer
Actinium Pharmaceuticals (ATNM) announced “encouraging” initial clinical results from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer, or mCRPC. The fin...
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day...
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
ATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatments In colorect...
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to fe...
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced ind...
Actinium Pharmaceuticals to present ATNM-400 data at EANM
Actinium Pharmaceuticals (ATNM) announced three presentations, including an oral presentation and two e-posters, highlighting preclinical data supporting ATNM-400’s broad potential at the 39th Annual ...
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal ca...
Actinium Pharmaceuticals Proxy statement: Proxy filing
Actinium Pharmaceuticals filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals an...
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation o...
Actinium Pharmaceuticals appoints Matt David as CFO
Actinium Pharmaceuticals (ATNM) appointed Matt David as CFO. David joins Actinium from CorMedix, where he most recently served as EVP and Chief Business Officer. He joined CorMedix in 2020 as…
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sa...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advance...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
Actinium Pharmaceuticals Quarterly report: Q2 2026
Actinium Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 7, 2026.
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026
Actinium Pharmaceuticals (ATNM) on June 2 presented new preclinical data on ATNM-400 in non-small cell lung cancer, or NSCLC, at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual…
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater th...
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide (Er...
Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer
Actinium Pharmaceuticals (ATNM) announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug dev...
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical thro...